EUVIMEDEUVIMED entdecken
Crossref

Aprepitant as add-on to standard antiemetic regimen for concurrent chemoradiotherapy induced nausea vomiting in head and neck cancer

Neetu Gupta, Shailley Sehgal, Niti Mittal

World Journal of Clinical Cases · 16.08.2026 · 14 (23)

DOI: 10.12998/wjcc.122960 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Clinical Cases, online erschienen am 16.08.2026. Verfasst von Neetu Gupta und 2 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND There is dearth of literature with respect to specific antiemetic guidelines for the concurrent chemoradiotherapy (CCRT) induced nausea and vomiting. Evidence regarding the routine use of NK1 receptor antagonists in CCRT settings also remains limited. AIM To evaluate the efficacy and safety of aprepitant as add-on to standard antiemetic therapy (ondansetron and dexamethasone) for prevention of CCRT-induced nausea and vomiting in patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC). METHODS This randomized, double-blind, placebo controlled clinical trial was conducted at a regional cancer institute in a public tertiary care hospital in North India. Treatment naïve patients with histologically confirmed LAHNSCC started on weekly cisplatin-based CCRT were randomized into 2 groups viz. Group A: Aprepitant plus standard antiemetic regimen; and Group B: Standard antiemetic regimen. Patients were followed up till four days after CCRT cycle. Primary outcome of complete response was assessed during acute (0-24 hours) and delayed phase (day 2-5). Secondary outcomes included complete protection (CP), degree of nausea and vomiting, rescue medication use and safety analysis. RESULTS Eighty-six patients were enrolled (43 per group). The aprepitant regimen significantly improved acute-phase complete response (97.7% vs 81.4%; P = 0.014). Delayed-phase complete response was numerically higher in the aprepitant group (74.4% vs 69.7%) but the difference was not statistically significant (P = 0.63). CP was better in the aprepitant group. Mean nausea intensity score and rescue medication use were lower in Group A. Both regimens were well tolerated with comparable adverse events. CONCLUSION Addition of aprepitant provides superior acute-phase control of CCRT-induced nausea and vomiting and improves nausea without compromising safety. Larger studies with multiple CCRT cycles are needed to further provide confirmatory evidence in this direction.

Zitieren

APA

Gupta, N., Sehgal, S., & Mittal, N. (2026). Aprepitant as add-on to standard antiemetic regimen for concurrent chemoradiotherapy induced nausea vomiting in head and neck cancer. World Journal of Clinical Cases, 14(23). https://doi.org/10.12998/wjcc.122960

Vancouver

Gupta N, Sehgal S, Mittal N. Aprepitant as add-on to standard antiemetic regimen for concurrent chemoradiotherapy induced nausea vomiting in head and neck cancer. World Journal of Clinical Cases. 2026;14(23). doi:10.12998/wjcc.122960

BibTeX
@article{Gupta2026,
  author = {Gupta, Neetu and Sehgal, Shailley and Mittal, Niti},
  title = {Aprepitant as add-on to standard antiemetic regimen for concurrent chemoradiotherapy induced nausea vomiting in head and neck cancer},
  journal = {World Journal of Clinical Cases},
  year = {2026},
  volume = {14},
  number = {23},
  doi = {10.12998/wjcc.122960}
}
Kostenlos starten →